Antiparkinsonian activity of a single oral dose of PHNO.
PHNO, a new D-2 agonist, was investigated in five patients with Parkinson's disease. In an acute, open, oral, dose-ranging study comparing benefit from single doses, 4 mg of PHNO was found to be equivalent to one tablet of Sinemet 25/250 mg. Adverse reactions were those anticipated for a dopaminomimetic agent. Because of its novel structure and apparent transcutaneous penetration, further studies on PHNO are desirable.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002230:Carbidopa / Q000008:administration & dosage / Q000627:therapeutic use; D015259:Dopamine Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010078:Oxazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D011930:Reaction Time
D015259:Dopamine Agents; D004338:Drug Combinations; D010078:Oxazines; C009265:carbidopa, levodopa drug combination; C042631:naxagolide; D007980:Levodopa; D002230:Carbidopa